Altered iron metabolism, transferrin receptor 1 and ferritin in patients with colon cancer

Prutki, Maja; Poljak‐Blaži, Marija; Jakopović, Marko; Tomas, Davor; Stipančić, Igor; Žarković, Neven

doi:10.1016/j.canlet.2005.07.001

Cited by 98 publications

(67 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In antitumor approaches, for example, numerous constructs have been reported that target transferrin receptor, [39][40][41][42][43][44][45] since this receptor has been reported to be expressed at levels approximately twofold higher in tumors than in normal tissues. 46,47 Intuitively, a twofold difference may not provide a sufficient differential between tumor and normal tissue to confer tumor selectivity, unless the dose-response curve of the therapeutic entity is very steep.…”

mentioning

confidence: 99%

Stem and progenitor cell-mediated tumor selective gene therapy

2008

View full text Add to dashboard Cite

The poor prognosis for patients with aggressive or metastatic tumors and the toxic side effects of currently available treatments necessitate the development of more effective tumor-selective therapies. Stem/progenitor cells display inherent tumor-tropic properties that can be exploited for targeted delivery of anticancer genes to invasive and metastatic tumors. Therapeutic genes that have been inserted into stem cells and delivered to tumors with high selectivity include prodrug-activating enzymes (cytosine deaminase, carboxylesterase, thymidine kinase), interleukins (IL-2, IL-4, IL-12, IL-23), interferon-b, apoptosis-promoting genes (tumor necrosis factor-related apoptosis-inducing ligand) and metalloproteinases (PEX). We and others have demonstrated that neural and mesenchymal stem cells can deliver therapeutic genes to elicit a significant antitumor response in animal models of intracranial glioma, medulloblastoma, melanoma brain metastasis, disseminated neuroblastoma and breast cancer lung metastasis. Most studies reported reduction in tumor volume (up to 90%) and increased survival of tumor-bearing animals. Complete cures have also been achieved (90% disease-free survival for 41 year of mice bearing disseminated neuroblastoma tumors). As we learn more about the biology of stem cells and the molecular mechanisms that mediate their tumor-tropism and we identify efficacious gene products for specific tumor types, the clinical utility of cell-based delivery strategies becomes increasingly evident.

show abstract

mentioning

confidence: 99%

Stem and progenitor cell-mediated tumor selective gene therapy

2008

View full text Add to dashboard Cite

show abstract

“…Upregulation of CD71 in cancer cells is associated with malignant transformation. CD71 expression is particularly increased in metastatic and drug resistant tumors [33][34][35][36][37][38]. This makes CD71 both a tumor marker and a possible system for the delivery of small-molecule drugs to these cells by CD71-mediated endocytosis [39][40][41][42][43][44].…”

Section: Discussionmentioning

confidence: 99%

Use of Ferritin-Based Metal-Encapsulated Nanocarriers as Anticancer Agents

et al. 2017

View full text Add to dashboard Cite

Abstract:The ability of ferritin to bind and deliver metals and metal-based drugs to human neuroblastoma SH-SY5Y cells was studied. We used heavy chain (H) ferritin-based metal-containing nanocarriers to test whether these constructs, which are able to cross the blood-brain barrier, may be used for the delivery of toxic molecules to brain cells, and to study their effect on the viability and cellular redox homeostasis of human neuroblastoma cells. We show that metal-containing nanocarriers are efficiently captured by SH-SY5Y cells. Iron-containing nanocarriers have a proliferative effect, while silver and cisplatin-encapsulated nanocarriers determine concentration-dependent neuroblastoma cell death. This work is a proof of concept for the use of ferritins for the delivery of toxic molecules to brain tumors.

show abstract

“…70% of patients and low RBC in about half of the group. 24 Moreover, low TIBC, which is mostly seen in anemia of chronic disease, was found in almost 60% of the group. 25 …”

Section: Resultsmentioning

confidence: 95%